Over the past three months I, probably like most have benefitted from the movement in small micro - cap stock that have risen heavily on increased liquidity. The next stock, despite having benefitted from a massive surge in share price back in April, that I have focused on is Ultrasis. This company is poised to secure the ever increasing Mental Health Market both at home and in the US (Several lucrative contracts already announced)through its suite of highly effective software.

The companies web address is as follows http://www.ultrasis.co.uk

I for one have gone heavily into this stock and am prepared to wait for the realisation of its potential to kick in .I would advise others to do so

DYOR

buyers coming back in now.

buy time again,last opportunity

ULTRASIS Action Type: Proposed Description: Subject to approval at meetings to be held on 4th May 2004, the company will cancel the listing of its securities on the Official List and apply for the admission of its securities to trading on AIM.

As shares listed on AIM are not eligible to be held within a PEP or ISA account, following the transfer we will write to such clients regarding alternative arrangements for holding the shares.

above posted as corporate action -

would above affect the price in anyway - ??any one please enlighten. Thanks

pension it all depends on how many have holding in pep and if they all come onto market at same time, i wrote to jeremy lacey 2-3 weeks ago asking for a article to be in shares mag on the pros and cons of a co going from full listing to aim i have had no reply so far. cheers woodie

WOODIE
I am out at the moment, going from full listing to aim confirmed one of your earlier posts regarding this move, also the raising of additional funding for acquisitions for what purpose the extra dilution of shares is what you predicted and it's now in the rns, I will be watching from the side lines and may get back in.
Thanks WOODIE for your advice on this stock.

Here is an extract. The only thing that is lacking in the report is that there have not been any new contracts but they will be coming.

"Chief executive Graham Lewis said business has continued to develop steadily for the first six months. Cost management has been stringent and the group said order input for the first 3 months of 2005 has again been positive.

However, he said the impact of this is not reflected in the results to end-Jan 2005."

grandadg90
As I said I may get back in on this, any new deal will see the sp heading north again.

Thanks Woodie for your post 204.

Grandad - I too am a holder - added big chunks Wed and Thurs to my previous holding. Now we wait and see. Meanwhile looks like two "chapatis" instead of three for a while !! Just joking - though will help the waist line!! I am not complaining SBT have been good to me last few days and that more than compansated the loss here.
cheers folks - nice weekend p/271

driver thanks for comment the sp is holding up well,driver when the terms of the fundraising is out in the open and we know the terms of rights issue it might be time to move back in or increase holdings. the results for the full year wont show much headway from here cheers woodie

rns release may 23 date of move to aim.

Ultrasis PLC
03 May 2005


Ultrasis PLC

New Appointment Announcement

ULTRASIS APPOINTS NEW UK DIRECTOR OF SALES
Interactive healthcare specialists, Ultrasis plc, have appointed a new UK
Director of Sales in order to harvest increasing market potential. Assuming his
new position as of 1st of May, John Smith will develop the market for the
company's range of computer based products, both amongst Primary Care Trusts
keen to use effective drug-free alternatives in the treatment of depression, as
well as employers who in line with current legislation wish to take proactive
steps to reduce stress in the workplace.

Graham Lewis, Chief Executive of Ultrasis commented; 'Mental health including
stress-related illness is now widely acknowledged as the number one cause of
workplace absenteeism, a fact underlined by the Health and Safety Executive's
move in November 2004 to issue new guidelines to employers on this issue.
Combined, these factors mean that the market for our products is growing
rapidly. John's appointment will give us increased capacity to actively ensure
Ultrasis take full advantage of this market opportunity.'

John, who was previously an Executive Director of a national charity, Mental
Health Matters, has extensive experience within the NHS, most recently as
Director of Innovation and Redesign for the 5 Boroughs Partnership NHS Trust
providing specialist mental health services to the people of Warrington, St
Helens, Knowsley, Wigan and Halton. One of his key achievements during this time
was the introduction of Ultrasis Relief Series to the population of St Helens as
a treatment for depression and anxiety and was very impressed with the results.

'Having witnessed very favourable experiences from the customer perspective, I
truly believe in the Ultrasis product range and am delighted to have the
opportunity to develop it on a national scale,' John commented. 'I feel there is
huge scope for these drug-free treatments for stress, anxiety and depression
which are not only proven and cost-effective to implement but are also wanted by
the people who experience the effects of mental ill-health.'

Graham added; 'I see John's appointment as a very positive move for Ultrasis.
His background in the field of mental health, network contacts and direct
experience of our product's effectiveness will be great assets in developing
Ultrasis' continued growth. We believe our products are the best on the market,
and now recommended by NICE for use in the NHS, we are very pleased that John
has joined forces with us.'
ENDS

Enquiries
Ultrasis Plc
Charlie Martin, Executive Director
0207 566 3900




This information is provided by RNS
The company news service from the London Stock Exchange

SAM24 WOODIE
I am back in on this one I think the future looks good at the price I paid even taking the fund raising into account, it is inevitable that there will be new deals coming through with the new appointment of UK Director of Sales in place.

driver,

Welcome back.

driver ,it is a slim chance you will lose money on this one at this price once the fundraising and move to aim is out of the way sp should move up. cheers woodie

WOODIE
Not unless there is a deal announced before the move, any way I cannot keep my eye on it all the time, I am in now, the sp can do it's own thing in the short term, long term this is a stock to have in your portfolio.

driver i agree.cheers woodie

where is agm statement?

Ultrasis PLC
04 May 2005


Ultrasis PLC

4 May 2005

Ultrasis plc

Results of Annual General Meeting and Extraordinary General Meeting

The Company announces that all resolutions were passed at the annual general
meeting held earlier today.

Also at the extraordinary general meeting of holders of 6 per cent Convertible
Loan Stock 2008 the single resolution was unanimously passed.

Graham Lewis, Chief Executive
Ultrasis plc
020 7566 3900


4 May 2005




This information is provided by RNS
The company news service from the London Stock Exchange

PRESS INFORMATION
Release immediate
5th May 2005

CALL FOR PARTIES TO PUT WORK RELATED STRESS ON THE POLITICAL AGENDA

With stress now officially the number one cause of absenteeism costing the economy an estimated 3.7 billion a year a leading interactive healthcare specialist believes the issue should be placed higher up on the political agenda.

Absenteeism due to workplace stress is a growing problem for employers resulting in the loss of some 13 million working days each year, commented Graham Lewis, Chief Executive of interactive healthcare specialists, Ultrasis plc. This is bad news for the economy as well as a headache for employers, and were surprised that none of the major parties is making an issue of this, particularly as there are cost-effective steps which can be taken to tackle the problem.

Ultrasis have pioneered the development of a number of interactive packages, some using Cognitive Behavioural Therapy (CBT) techniques, which enable employers to identify the extent of stress and anxiety amongst staff and, where appropriate, take remedial action. As well as being highly effective and drug-free, the programmes have low set-up and operating costs, increasing their appeal to organisations who want to deal with the problem in a cost-effective way.

Last year the Health and Safety Executive introduced new stress management guidelines which all employers are now required to follow, which demonstrates that the government recognises the importance of the problem. Whilst the issue of stress related absenteeism is recognized by all three main parties, it is surprising that their respective policies are not being more openly debated, commented Graham Lewis.

He added, The scale of this growing problem would suggest that this is an issue which cant be ignored and merits higher priority on the agendasfor all parties. The benefits of a more proactive approach to tackling stress are all too obvious both for employers and the economy in general.


For further information about ways to tackle work related stress, please visit www.calmworkplace.com
ENDS



Caption for photograph
Costing the economy an estimated 3.7 billion a year, Ultrasis CEO Graham Lewis, is calling for the main political parties to put the issue of absenteeism due to work related stress on the political agenda.
Notes for Editors
Ultrasis Plc is a leader in the development of a new generation of interactive solutions, which help people manage their well-being. The Company has created innovative clinically proven, drug-free computerised solutions that, based on the integration of advanced multimedia software, and expert knowledge in health and psychology help people tackle stress and a full spectrum of chronic conditions.
The Chartered Institute of Personnel and Development has in a recent study cited stress as the number one cause of absenteeism in the workplace. Stress related illness is estimated to cost 3.7 billion a year in lost productivity and health care costs, amounting to a third of the 11.6 billion total lost to illness.
For further information about Ultrasis, please contact Dr Charlie Martin or Graham Lewis on telephone +44 (0)20 7566 3900 or email to info@ultrasis.com
Media enquiries
a Walker, Nyans Communications
Tel: 01564 777 231
Fax: 01564 778 080
asa@nyans.co.uk

Foam treatment for varicose veins

More than a fifth of adults get varicose veins
Injecting patients with a foam that expands in the blood vessels can successfully treat troublesome varicose veins, say doctors.
Between 20% and 30% of adults develop varicose veins, usually later in life or during pregnancy.

As well as looking unpleasant, varicose veins can ache, throb and itch.

More than 50 patients at Ealing Hospital in London have received the foam therapy with good results, says consultant Mr George Geroulakos.

Fast foam

If they are small, varicose veins may be controlled with conservative methods, such as compression bandages or stockings.

But larger or more complicated varices cases will need surgery.

The early and interim results are really promising

Mr George Geroulakos

This can involve stripping the veins, tying them off or injecting an agent to close the vein, which is called sclerotherapy.

Sclerotherapy has some advantages over surgical stripping.

It can be done under local rather than general anaesthetic and leaves only one small scar in the groin rather than numerous scars on the leg.

"With the conventional stripping technique, the patient has to stay off work for about eight days after.

"With the foam therapy, they can go back within days," said Mr Geroulakos, who is also a consultant for the Hammersmith Hospitals NHS Trust.

Doctors have been using liquid sclerotherapy for years. But a newer way is to use a foam, guided with the help of ultrasound imaging.

Closing the vein

In contrast to liquid, foam is not diluted once injected, so less is needed and it remains in the vein for a longer time.

The foam works by pushing the blood out of the way and is able to make better contact with the inside of the vein walls.

All of these factors mean it could work better than liquid sclerotherapy, according to Mr Geroulakos.

"Sometimes the liquid can leak outside of the vein and this can cause a chemical sore or ulcer.

"We think complications should be less common with the foam.

"Plus you can see exactly where the foam is with ultrasound. It casts a shadow that can be seen with the machine. You can see every individual vein, which is a major advantage," he said.

Mr Geroulakos has been treating patients with the foam technique for two years. "The early and interim results are really promising, but we have not been doing it long enough to know about the long-term results," he said.

About a fifth of patients who have their varicose veins treated with stripping will need repeat treatment within five years because the problem comes back. But it is not yet clear whether the same is true with foam therapy.

A single injection of the foam is enough to treat a half metre length of vein.

Afterwards, the patient wears a compression stocking continuously for two weeks and then during the day only for another week.



From the BBC site http://news.bbc.co.uk/2/hi/health/4510709.stm